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Positron emission tomography (PET) has become a valuable interdisciplinary tool
 (Seeman et al., 1990) 
affinity D2 receptor radiotracer 1lC-N-methylspiroperidol (1'C-NMSP) demonstrated a two-to three-fold increase in ligand competition in schizophrenic patients when compared to normal
controls (Wong et al., 1986) , while the noncompetitive D2 radiotracer 1lC-raclopride demonstrated no change in competition between schizophrenic patients and controls (Farde et al., 1987) , A later discovery was that endogenous dopamine (DA) released into the synapse competes with llC-raclopride for D2 receptor binding sites (Seeman et al., 1990) , whereas 1lC-NMSP is less sensitive to the influence of endogenous dopamine (Logan et al., 1992) and possibly a more effective tool for measuring receptor physiology. Further, while Farde et al., demonstrated no change in the bil~ding characteristics of llC-raclopride between schizophrenic patients and normal controls, Breier et al. (1997) 
recently demonstrated amphetamine-induced increases in dopamine release produce less 1lC-raclopride binding in schizophrenic patients
when compared to healthy controls given the same challenge (Breier et al., 1997 (Wong et al., 1986) and Farde (Farde et al., 1987) (Dewey et al., 1992a) (Logan et al., 1990) ; (Dewey et al., 1990c (Logan et al., 1990 Frey et al., (Frey et al., 1990) to study muscarinic receptors with 11C-tropanyl benzilate and by Koeppe et al., (Koeppe et al., 1991) (Olney and Farber, 1995) . (Arnfied and Randrup, 1968; Bloom et al., 1965; Costall and Olley, 1971; Ehlert et al., 1981; Lehmann and Langer, 1982 (Davies and Verth, 1977; Meltzer and Stahl, 1976) .
Some studies have hypothesized that cholinergic hyperactivity may nnderlie the negative symptoms associated with schizophrenic illnesses as well (Tandon and Greden, 1989) . The highest levels of choline acetyltransferase and cholinergic receptors in the human CNS are found in the striatum and the majority of cholinergic cells are interneurons (Cortes et al., 1987; Fibiger, 1982) . These cholinergic intemeurons provide excitatory input to local GABA neurons, which in turn are thought to inhibit the activity of dopaminergic neurons (Bunney and Aghaj anian, 1976) . et al., 1990a (Wesemann et al., 1983; Stanley and Mann, 1984; Pucilowski and Kostowski, 1983; Bowen et al., 1983; Crow et al., 1984; Middlemiss et al., 1986; Reynolds et al., 1984 (Joyce et al., 1993; Joyce, 1993; Zazpe et al., 1994) ; (Kapur and Remington, 1996 (Tsukada et al., 1999) .
Our initial primate investigations demonstrated the binding of 18F-NMSP was reduced by 13% after the animals received an injection of benztropine (an anticholinergic agent) when compared to control animals receiving no benztropine (Dewey
By decreasing serotonergie activi~with altanserin, we quantljled seconday increases in brain dopamine by measuring decreases in llC-raclopride binding (indicating increased competition from endogenous dopamine). Next, we increased serotonergic activity with citalopram administration and demonstrated decreases in endogenous dopamine release with increased 11C-raclopride binding.
In an attempt to extend this finding to human subjects, we used fenfluramine, a selective 5-HT reuptake inhibitor and releasing agent, to increase serotonergic activity (Smith et al., 1997 (Tiihonen et al., 1996) or acute (Vollenweider et al., 1999) (DeFeudis, 1984; Koob, 2000; Dewey et al., 1998 
GABAergic modulation of dopamine in substance abuse
We have also used 1lC-raclopride binding and PET to explore the inhibitory subsequent potential of GVG on the brain response to substances of abuse. The rewarding effects of psychostirnulants have been associated with their ability to increase striatal dopamine levels (Volkow et al., 1999) .
The system of primary interest in these conditions involves the mesocorticolimbic dopaminergic
projections from the ventral tegmental area (VTA) and substantial nigra into the ventral striatum, medial prefrontal cortex, and amygdala, which participate in the neural processing of motivated behavior (Robbins et al., 1989) . Alterations in this system are thus hypothesized to play roles in mediating the euphoria and behavioral reinforcement associated with drugs of abuse (for review, see (McBride et al., 1999) (Di Chiara et al., 1993; Di Chiara et al., 1992 et al., 1998) , and reduced self-administration of cocaine (Kushner et al., 1999) and heroin (Xi and Stein, 2000) Gerasimov et al., 1999) , consistent with microdialysis studies (Gerasimov et al., 1999) .
To further investigate the specific properties of GVG that contribute to its efficacy as a potential anti-addictive agent, as well as to justify the ability of llC-raclopride to detect changes
induced by multiple pharmacologic manipulations, we administered the pure enantiomers of the racemic compound before an acute nicotine challenge (Schiffer et al., 2000) . (Lahti et al., 1995b; Lahti et al., 1995a) . We recently demonstrated the sensitivity of l*C-raclopride binding to changes in human brain activity induced by ketamine (Smith et al., 1998) Figure 3 .
support studies indicating that, as an anticonvulsant, the active S(+) enantiomer also retains the pharmacologic efficacy of GVG. Our microdialysis data corroborate our PET studies in that S(+)-GVG was as effective as the racemic compound at decreasing the extracellular NACC dopamine response to cocaine in rodents.
GABAergic modulation of dopamine in sckizophreniu
Here, it is clear that there is less llC-raclopride binding in the primate given PCP, whereas in the animal pretreated with GVG, llC-raclopride binding in the second scan is very similar to baseline.
This investigation demonstrated that it is possible to modulate glutamate-induced increases in dopamine with increased ,inhibitory GABA levels, and that this pharmacologic interaction can be measured with 1lC-raclopride binding and PET. This study is supported by our dialysis investigations employing a similar paradigm by measuring changes in extracellular
doparnine release after GVG pretreatment and a PCP challenge (Schiffer et al., submitted) . (Korsgaard et al., 1983; Thaker et al., 1983) . Additionally, it has been demonstrated that patients receiving long-term neuroleptic therapy are more vulnerable to psychostimulant abuse (Roberts and Vickers, 1984; Roberts and Vickers, 1987; Brady et al., 1990) (Wassef et al., 1999) . (Mulholland et al., 1992; Koeppe et al., 1992; Lee et al., 1991 (Dewey et al., 1990b) .
Modulation of cholinergic activity studied with llC-benztropine
Cholinergic cells in the striatum only represent a small population of striatal neurons, but
are able to modulate the excitability in this brain region due to their widespread axonal fields and high sensitivity to related neurotransmitter systems (Kincaid et al., 1998) et al., 1990) . For a review of our studies with the cholinergic ligand, 11C-benztropine, please see Table 2 .
. Studies investigating in vivo and in vitro acetylcholine release have demonstrated that dopamine controls cholinergic transmission in a facilito~manner both directly and indirectly (Damsma
Dopaminergic modulation ofacetylcholine
Our 
Serotonergic modulation of acetylcholine
The modulatory role of serotonin on acetylcholine activity has been extensively documented (Giovannini et al., 1998) ), and more recent theories propose serotonin stimulates acetylcholine release through increased dopaminergic activity in animals, consistent with our primate investigations (Ramirez et al., 1997) .
The dorsal and median raphe nuclei are the major sources of 5-HT in the CNS. 5-HT2 receptors have been localized to cortical cholinergic nerve terminals as revealed by the loss of these receptors secondary to lesions of the nucleus basalis of
Meynert (Quirion and Richard, 1985) . Serotonergic enervation to the striaturn is derived fi-om the dorsal and medial raphe nuclei, which project to the striatum, pallidum, and substantial nigra (mainly the pars compacta). Serotonin has been shown to inhibit striatal ACh release (Euvrard et al., 1977) ; (Guyenet et al., 1977) and depletion of endogenous 5-HT increased the release of striatal ACh (Visi et al., 1981) . Gillet and coworkers (Gillet et al., 1985) demonstrated that exogenously administered 5-HT, 5-HT agonists, or fluoxetine, an inhibitor of 5-HT uptake, reduced striatal ACh release, whereas methylsergide, a 5-HT agonist, increased ACh efflux in the caudal striatum (Jackson et al., 1988) . However, Robinson (Robinson, 1983) 
found no effect of 5-HT on striatal ACh levels but instead reported an inhibition of Ach in cortex and
hippocampus.
We examined the modulation of acetylcholine by serotonin by measuring the effect of the serotonin antagonist altanserin on the binding of llC-benztropine in primates (Dewey et al., 1993a) . Decreasing serotonin activity with altanserin led to a decrease of striatal benztropine binding of -30'Yo; which is consistent with profound regional increases in acetylcholine release.
These results confirm data from other studies indicating serotonin exerts a predominantly inhibitory influence on cholinergic interneurons in the rat striatum (Visi et al., 198 1).
In sum, decreasing serotonin activity with altanserin produced increases in synaptic acetylcholine levels, measured by decreases in 11C-benztropine binding. (Scatton and Bartholini, 1980) . (DeBoer and Westerink, 1994) , but also with glutamatergic (Moratalla and Bowery, 1991) and dopaminergic neurons in the striatum (Bowery et al., 1990 et al., 1998; Moratalla and Bowery, 1991) . A recent microdialysis study demonstrated that the GABAergic system appears to inhibit tonically the output of striatal acetylcholine via GA13AA
GABAergic modulation of acetylcholine
GABAergic neuronal terminals make contact not only with cholinergic neurons
receptors, but not via GABAB receptors (DeBoer and Westerink, 1994 (Scatton and Bartholini, 1980) . Taken with our previous work using * lC-raclopride and GVG (Dewey et al., 1992b) LY163502, trans-(-)-5,5a,6,7,8,9a,10-octahydro-6- Tiihonen J, Kuoppamaki M, Nagren K, Bergman J, Eronen E, Syvalahti E and Hietala J (1996) Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology, 126,277-80. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K and Harada N (1999) Psychiatry Res, 49,219-37. Visi ES, Harsing LGJ and Zsilla G (1981) Evidence of the modulatory role of serotonin in acetylcholine release born striatal intemeurons. Brain Res, 212, 89-99. Volkow ND, Fowler JS and Wang GJ (1999) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. JPsychopharmacol, 13, 337-45. Vollenweider FX, Vontobel P, Hell D and Leenders KL (1999) 
